Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect Amphastar Pharmaceuticals to post earnings of $1.01 per share and revenue of $188.78 million for the quarter.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH opened at $30.75 on Wednesday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The business’s 50-day simple moving average is $36.61 and its two-hundred day simple moving average is $43.24. The stock has a market cap of $1.48 billion, a PE ratio of 10.25, a P/E/G ratio of 2.07 and a beta of 0.81. Amphastar Pharmaceuticals has a 52 week low of $30.34 and a 52 week high of $56.38.

Analysts Set New Price Targets

A number of research firms have commented on AMPH. Piper Sandler cut Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $50.33.

Insider Transactions at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the completion of the transaction, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.